Literature DB >> 19958839

Modulation of matrix remodeling by SPARC in neoplastic progression.

Alexandre Chlenski1, Susan L Cohn.   

Abstract

SPARC is a matricellular glycoprotein that mediates interactions between cells and their microenvironment. It is produced at sites of tissue remodeling, where it regulates matrix deposition and turnover, cell adhesion, and signaling by extracellular factors, exerting profound effects on tissue architecture and cell physiology. During extensive matrix remodeling in neoplastic progression, SPARC is expressed in cancer-associated stroma and in malignant cells of some types, affecting tumor development, invasion, metastases, angiogenesis and inflammation. SPARC-induced changes in the tumor microenvironment can suppress or promote progression of different cancers depending on the tissue and cell type. Understanding the mechanism of matrix remodeling and its regulation by SPARC is essential for the development of new treatment strategies for highly aggressive cancers. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19958839     DOI: 10.1016/j.semcdb.2009.11.018

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  60 in total

1.  The influence of a biologically relevant substratum topography on human aortic and umbilical vein endothelial cells.

Authors:  Clayton T McKee; Joshua A Wood; Irene Ly; Paul Russell; Christopher J Murphy
Journal:  Biophys J       Date:  2012-03-06       Impact factor: 4.033

2.  Decorin gene upregulation mediated by an adeno-associated virus vector increases intratumoral uptake of nab-paclitaxel in neuroblastoma via inhibition of stabilin-1.

Authors:  Zijun Zhen; Kaibin Yang; Litong Ye; Zhiyao You; Rirong Chen; Ying Liu
Journal:  Invest New Drugs       Date:  2017-06-20       Impact factor: 3.850

Review 3.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

4.  Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells.

Authors:  Masaki Iwasa; Yasuo Miura; Aya Fujishiro; Sumie Fujii; Noriko Sugino; Satoshi Yoshioka; Asumi Yokota; Terutoshi Hishita; Hideyo Hirai; Akira Andoh; Tatsuo Ichinohe; Taira Maekawa
Journal:  Int J Hematol       Date:  2017-01-02       Impact factor: 2.490

5.  Emerging therapies in pancreas cancer.

Authors:  Adam Kotowski; Wen W Ma
Journal:  J Gastrointest Oncol       Date:  2011-06

6.  A fragment of SPARC reflecting increased collagen affinity shows pathological relevance in lung cancer - implications of a new collagen chaperone function of SPARC.

Authors:  S N Kehlet; T Manon-Jensen; S Sun; S Brix; D J Leeming; M A Karsdal; N Willumsen
Journal:  Cancer Biol Ther       Date:  2018-08-01       Impact factor: 4.742

7.  Loss of SPARC in bladder cancer enhances carcinogenesis and progression.

Authors:  Neveen Said; Henry F Frierson; Marta Sanchez-Carbayo; Rolf A Brekken; Dan Theodorescu
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

Review 8.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

9.  Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

Authors:  Alexandre Chlenski; Lisa J Guerrero; Radhika Peddinti; Jared A Spitz; Payton T Leonhardt; Qiwei Yang; Yufeng Tian; Helen R Salwen; Susan L Cohn
Journal:  Mol Cancer       Date:  2010-06-04       Impact factor: 27.401

10.  SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression.

Authors:  Gerardo Botti; Giosuè Scognamiglio; Laura Marra; Francesca Collina; Maurizio Di Bonito; Margherita Cerrone; Bruna Grilli; Annamaria Anniciello; Renato Franco; Franco Fulciniti; Paolo Antonio Ascierto; Monica Cantile
Journal:  Virchows Arch       Date:  2014-07-04       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.